Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program
20 March 2018 - 11:30PM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage
biopharmaceutical company focused on the discovery and development
of precision genetic medicine to treat rare neuromuscular diseases,
announced today the launch of its Route 79, The Duchenne
Scholarship Program, an annual scholarship for students diagnosed
with Duchenne muscular dystrophy (DMD). The Route 79 program is
designed to help students with DMD pursue their post-secondary
educational goals. Scholarships of up to $10,000 will be awarded to
10 individuals chosen by an independent committee of DMD community
members based on an applicant’s community involvement and a
personal essayi.
“We are pleased to announce the launch of our
Route 79, The Duchenne Scholarship Program,” said Douglas Ingram,
Sarepta’s president and chief executive officer. “The road traveled
by each individual with DMD is distinct. We are honored to help
empower the educational goals of those DMD students who have chosen
higher education; and we are excited to follow the achievements and
societal contributions these remarkable individuals can make in the
future.”
The underlying cause of DMD is a mutation or
error in the gene coding for dystrophin. Dystrophin is an essential
protein that plays a pivotal role in muscle structure, function and
preservation. The numerical significance of the scholarship’s name,
Route 79, ties to the 79 exons of the dystrophin gene.
To apply for a scholarship through the Route 79
program, applicants must be either a high school senior or a
college freshman, sophomore or junior in good academic standing,
accepted to or enrolled into an accredited college or university or
a trade, technical or vocational school located in the United
States and be diagnosed with DMD.
Applications will be accepted until May 31, 2018
at 11:59 PM PT. Recipients will be announced in July 2018 and
awards will be distributed by mid-August, in time for fall 2018
enrollment. Students may apply by clicking here.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage
biopharmaceutical company focused on the discovery and development
of precision genetic medicine to treat rare neuromuscular diseases.
The Company is primarily focused on rapidly advancing the
development of its potentially disease-modifying Duchenne muscular
dystrophy (DMD) drug candidates. For more information, please visit
www.sarepta.com.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan,
617-274-4052 iestepan@sarepta.com or W2O Group Brian Reid,
212-257-6725 breid@w2ogroup.com
i No consideration will be given to whether or not an applicant
was previously, is currently, or expects to be in the future,
undergoing treatment with a Sarepta product or investigational
product.
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2023 to Apr 2024